|
|
Article: Enzo Biochem Executive Says Oral Immune Regulation Platform Shows "Therapeutic Promise".
- Article from:
- Biotech Week
- Article date:
- November 18, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Enzo Biochem, Inc. (NYSE:ENZ) reported on the Company's therapeutic platforms utilizing oral immune regulation for immune mediated diseases at the Bio-Europe 2009 15th Annual International Conference here calling it a "bright area of therapeutic promise."
"Our therapeutics subsidiary has long viewed oral immune regulation as an exciting and promising platform and one that we continue to pursue through studies involving treatment candidates for unmet medical needs," the meeting was told by David Goldberg, Enzo's Vice President, Corporate Development. "Additionally, as we grow our Life sciences and Clinical Labs divisions, we are ...
Related newspaper, magazine, and journal articles:
|
|
Article: Enzo Biochem to Present at the Lazard Capital ...
Biotech Week;
December 3, 2008 ;
534 words
... ... in New York City (see also Enzo Biochem, Inc.). The audio portion ... Keywords: Biotechnology Business, Enzo Biochem, Leading Biotechnology Company, Enzo Biochem Inc. This article was prepared by Biotech Week editors from staff and other ...
|
|